Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide

Abstract Background Targeting influential factors in resistance to chemotherapy is one way to increase the effectiveness of chemotherapeutics. The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway overexpresses in chronic lymphocytic leukemia (CLL) cells and appears to have a significant pa...

Повний опис

Бібліографічні деталі

Автори:	Atefeh Khodakarami, Mahsa Afsari Kashani, Atefeh Nazer, Armin Mahmoudsalehi Kheshti, Bentolhoda Rashidi, Vahid Karpisheh, Ali Masjedi, Shiva Abolhasani, Sepideh Izadi, Rafieh Bagherifar, Seyyed Sina Hejazian, Hamed Mohammadi, AliAkbar Movassaghpour, Abbas Ali Hosseinpour Feizi, Mohammad Hojjat-Farsangi, Farhad Jadidi-Niaragh
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2023-08-01
Серія:	Cell Communication and Signaling
Предмети:	Chronic lymphocytic leukemia (CLL) NRF2 Cyclophosphamide Rituximab Chemo-resistance
Онлайн доступ:	https://doi.org/10.1186/s12964-023-01213-1
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!